614 related articles for article (PubMed ID: 24412605)
1. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.
Ilmer M; Garnier A; Vykoukal J; Alt E; von Schweinitz D; Kappler R; Berger M
Mol Cancer Ther; 2015 Dec; 14(12):2712-21. PubMed ID: 26516161
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
[TBL] [Abstract][Full Text] [Related]
4. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients.
Wagner F; Henningsen B; Lederer C; Eichenmüller M; Gödeke J; Müller-Höcker J; von Schweinitz D; Kappler R
Eur J Cancer; 2012 Oct; 48(15):2442-50. PubMed ID: 22285179
[TBL] [Abstract][Full Text] [Related]
6. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
7. Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer.
Zhou Y; Zhao L; Xiong T; Chen X; Zhang Y; Yu M; Yang J; Yao Z
Breast Cancer Res Treat; 2013 Jul; 140(1):49-61. PubMed ID: 23807418
[TBL] [Abstract][Full Text] [Related]
8. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Innovations for Targeting Hepatoblastoma.
Garnier A; Ilmer M; Kappler R; Berger M
Anticancer Res; 2016 Nov; 36(11):5577-5592. PubMed ID: 27793881
[TBL] [Abstract][Full Text] [Related]
10. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
[TBL] [Abstract][Full Text] [Related]
11. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
12. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.
Zhang L; Wang L; Dong D; Wang Z; Ji W; Yu M; Zhang F; Niu R; Zhou Y
Cell Prolif; 2019 Jan; 52(1):e12527. PubMed ID: 30334298
[TBL] [Abstract][Full Text] [Related]
13. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells.
Wang L; Wang N; Zhang R; Dong D; Liu R; Zhang L; Ji W; Yu M; Zhang F; Niu R; Zhou Y
Life Sci; 2020 Sep; 256():117674. PubMed ID: 32380077
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
15. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
16. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
Nizam E; Köksoy S; Erin N
Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the role of substance P in the growth of brain tumors.
Harford-Wright E; Lewis KM; Vink R; Ghabriel MN
Neuroscience; 2014 Mar; 261():85-94. PubMed ID: 24374326
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
[TBL] [Abstract][Full Text] [Related]
19. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.
Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD
Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645
[TBL] [Abstract][Full Text] [Related]
20. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
